Fezolinetant,a new approved drug for the treatment of vasomotor symptoms in menopausal women
10.13699/j.cnki.1001-6821.2024.04.028
- VernacularTitle:治疗更年期女性血管舒缩症状的新药Fezolinetant
- Author:
Ting-Ting BIAN
1
;
Xin HE
Author Information
1. 扬州市妇幼保健院,扬州大学附属扬州妇幼保健院药学部,江苏扬州 225000
- Keywords:
Fezolinetant;
vasomotor symptoms;
menopausal women;
non-hormone therapy
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(4):611-614
- CountryChina
- Language:Chinese
-
Abstract:
Fezolinetant has been approved by the U.S.Food and Drug Administration(FDA)for the treatment of moderate/severe vasomotor symptoms(VMS)in menopausal women.The Fezolinetant tablet is for oral use and is a neurokinin 3 receptor(NK3R)antagonist that blocks neurokinin B binding on the KNDy neuron.Clinical studys indicate that Fezolinetant can reduce the frequency and severity of VMS and improve quality of life.The mechanism of action,pharmacodynamics,pharmacokinetics,clinical study and safety were introduced.
